spacer
home > ict > spring 2021 > medical cannabis in europe – an opportunity ripe for exploitation
PUBLICATIONS
International Clinical Trials

Medical Cannabis in Europe – An Opportunity Ripe for Exploitation



Medical cannabis has shown efficacy in trials and is being deployed legally in medical settings as a therapeutic, ranging from palliative care for cancer to appetite stimulant in patients with AIDS-related wasting syndrome. Yet, there is considerable variation in regulatory approaches between European countries.

Across Europe, some countries allow the use of medicinal products containing cannabinoids, while others allow the medical use of unauthorised products or preparations. Some countries have standalone medical cannabis programmes, some allow cannabis product manufacture, some do not allow manufacture but do permit cannabis imports, and some countries allow both.

Even the definition of ‘medical cannabis’ is not fully agreed, and the terminology has grey areas. Cannabidiol (CBD) is a chemical substance found in cannabis that has medical benefits. It is the key ingredient of approved medical cannabis drugs for children and adults with a rare form of epilepsy. CBD oils and supplements are also offered to consumers over the counter, but the efficacy of weaker consumer preparations is unproven. CBD is one of 113 identified cannabinoids in cannabis plants and accounts for up to 40% of the plant’s extract. Clinical research on CBD includes studies related to anxiety, cognition, movement disorders, and pain. CBD does not have the same psychoactivity as THC, the primary ingredient in cannabis that ‘gets you high’.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Peter Kohut is Director of Drug Safety at Arriello and an experienced EU QPPV. He began his career in biochemical research, before entering the pharmaceutical industry, where he has worked in clinical trials and post-marketing safety roles.
 

peter.kohut@arriello.com
 
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement